Deoratives Bannerbild

GBG research at SABCS 2022

01.12.2022

We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

San Antonio Breast Cancer Symposium 2022

GeparNuevo HTG (Denkert, C.)

Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy

PD4-02 spotlight poster discussion 4:
Wednesday, December 7, 2022: 7:00 – 8:15. Hemisfair Ballroom 1&2.

PENELOPE-B HER2-Low (Denkert, C.)

Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

HER2-06 poster presentation session at HER2 Low: A Separate Entity Special Session:
Wednesday, December 7, 2022, 9:45 - 11:00. Hall 3.

GeparNuevo Immunomarkers blood (Seliger, B.)

Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients

PD9-04 spotlight poster discussion 9
Wednesday, December 7, 2022: 17:00-18:15. Hemisfair Ballroom 1&2.

AMICA Trial (Decker, T.)

Maintenance therapy with ET and Ribociclib after 1st line chemotherapy (CT) in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (BC): a phase II trial (AMICA)

P3-01-09 poster session 3
Wednesday, December 7, 2022: 17:00-18:15. Hall 1.


CAPItello-291 Trial (Turner, N.)

Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

GS3-04 oral presentation
Thursday, December 8, 2022: 9:15-9:30. Hall 3.

Challenging Types of Breast Cancer

Moderator: Bora Lim, MD • Pathologic aspects Jorge S. Reis-Filho, MD, PhD • Metaplastic Alexandra Thomas, MD, FACP • Inflammatory Filipa Lynce, MD • Lobular/pleomorphic Sibylle Loibl, MD, PhD

EDUCATIONAL SESSION BLOCK #3B
Thursday, December 8: 15:00-17:00 (16:30-17:00). Stars at Night Ballroom 1&2.

GeparOLA Trial – Long-Term Survival Data (Fasching, P.A.)

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

GS5-02 oral presentation
Friday, December 9, 2022: 12:15-12:30. Hall 3.

Locoregional Recurrence, Triple Negative Breast Cancer (Krug, D.)

Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy

PD15-06 spotlight poster discussion 15
Thursday, December 8, 2022: 17:00-18:15. Hemisfair Ballroom 1&2.

PENELOPE-B, PALLAS Trials (Loibl, S.)

Development and validation of a composite biomarker predictive of Palbociclib + endocrine treatment benefit in early breast cancer: PENELOPE-B and PALLAS Trials

PD17-05 spotlight poster discussion 17
Friday, December 9, 2022: 7:00-8:15. Stars at Night Ballroom 1&2.

PENELOPE-B Immune Markers (Knudsen, E.S.)

Immunohistochemical markers and determinants of clinical response in the Penelope-B trial

PD17-06 spotlight poster discussion 17
Friday, December 9, 2022: 7:00-8:15. Stars at Night Ballroom 1&2.


San Antonio Breast Cancer Symposium 2022

News

  • 28.02.2023  Annual Scientific Report 2022 erschienen

    Annual Scientific Report 2022 erschienen

    Der Annual Scientific Report 2022 bietet einen Überblick über die Ergebnisse laufender Studien, wichtige Vorträge und Forschungsposter des vergangenen Jahres.

    Mehr ...
  • 23.01.2023  St.Gallen International Breast Cancer Conference 2023

    St.Gallen International Breast Cancer Conference 2023

    Die 18. “St.Gallen International Breast Cancer Conference” findet vom 15. – 18. März 2023 im Austria Center in Wien statt.

    Mehr ...
  • 09.01.2023  Schwangerschaft nach Krebs

    Gerne berichten wir in einer neuen Publikation „Schwangerschaft nach Krebs“ über den Einfluss von Krebstherapien auf die Ovarialfunktion und den damit zusammenhängenden Einfluss der Schwangerschaft selbst auf die Prognose.

    Mehr ...
  • 18.11.2022  Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd